Use of dermcidin in sterile inflammatory conditions

What is claimed is: 
     
         1 . A method of treating a sterile inflammatory condition in a subject comprising administering to the subject an amount of an isolated dermcidin peptide, or an active fragment thereof, or an active analog thereof, effective to treat a sterile inflammatory condition. 
     
     
         2 . The method of  claim 1 , wherein the sterile inflammatory condition is caused by or associated with ischemia-reperfusion in an organ in the subject. 
     
     
         3 . The method of  claim 1 , wherein the sterile inflammatory condition is caused by or associated with ischemia-reperfusion in a gastrointestinal tract, liver, lung, kidney, heart, brain or crushed limb of the subject. 
     
     
         4 . The method of  claim 1 , wherein the active analog of dermcidin is administered or used. 
     
     
         5 . The method of  claim 4 , wherein the active analog of dermcidin has a cysteine to serine substitution that prevents dimerization via disulfide bonds between cysteine 34 of two dermcidin peptides. 
     
     
         6 . The method of  claim 1 , wherein the active fragment of dermcidin is administered or used. 
     
     
         7 . The method of  claim 1 , wherein the peptide, analog or fragment is modified to improve its plasma half-life. 
     
     
         8 . The method of  claim 7 , wherein the peptide, analog or fragment is modified with PEGylation or mannosylation. 
     
     
         9 . The method of  claim 1 , wherein the amount of an isolated dermcidin peptide or an active fragment thereof or an active analog thereof is administered by intra-arterial, intravenous, intraventricular, or topical administration. 
     
     
         10 . The method of  claim 1 , wherein the subject is a human subject. 
     
     
         11 . A dermcidin analog comprising the following sequence: 
       
         
           
                 
               
                   YDPEAASAPGSGNPSHEASAAQKENAGEDPGLARQAPKPRKQRSSLLEKG 
                 
                     
                 
                   LDGAKK. 
                 
             
                
                
                
               
            
           
         
       
     
     
         12 . The dermcidin analog of  claim 11 , wherein the peptide, analog or fragment is modified with PEGylation or mannosylation. 
     
     
         13 . A composition comprising the dermcidin analog of  claim 11  in monomer form.